A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
NCT07011771
Recruiting
The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
08/14/2025
Locations: Rush University Medical Center, Chicago, Illinois +5 locations
Conditions: GBA1 Parkinson Disease
Register for Updates
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
NCT06953583
Recruiting
In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens with FA who are younger than 16 years old. The main objective of this study is to learn how BIIB141 works in the body and about its safety in children and teens who are 2 to 15... Read More
Gender:
ALL
Ages:
Between 2 years and 15 years
Trial Updated:
08/14/2025
Locations: UCLA Neurology Outpatient Clinic at Westwood, Los Angeles, California +26 locations
Conditions: Friedreich Ataxia
Register for Updates
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06961370
Recruiting
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
08/14/2025
Locations: Associated Retina Consultants - Phoenix - DocTrials - PPDS, Phoenix, Arizona +15 locations
Conditions: Geographic Atrophy, Age-related Macular Degeneration
Register for Updates
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT06973161
Recruiting
In DESTINY-Pan-Tumor \[DP-02\], DESTINY CRC02 \[DC-02\], and DESTINY-Lung01 \[DL-01\], T-DXd demonstrated tumor response across a broad range of HER2-expressing solid tumors, particularly IHC3+ patients. This study will use real-world data (RWD) to identify IHC3+ patients in the real world who received standard of care (SoC) and compare them with IHC3+ patients who received T-DXd in the referent trials. The tumors included are: non-small cell lung cancer \[NSCLC\], colorectal cancer \[CRC\], en... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/14/2025
Locations: Research Site, Spartanburg, South Carolina +26 locations
Conditions: Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer, Other Tumors
Register for Updates
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
NCT06856577
Recruiting
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an aver... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/14/2025
Locations: Adverum Clinical Site 223, Gilbert, Arizona +68 locations
Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Register for Updates
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Arthritis and Rheumatism Associates ARA Jonesboro, Jonesboro, Arkansas +150 locations
Conditions: Arthritis, Psoriatic
Register for Updates
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
NCT06908928
Recruiting
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: City of Hope, Duarte, California +4 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Acute Effects of THC in Older Adult
NCT06948136
Recruiting
The primary objective of this study is to determine if increasing age confers greater vulnerability to the acute A) cognitive (e.g., memory, attention, psychomotor function), B) subjective (e.g., anxiogenic and rewarding effects), and C) cardiovascular (heart rate and blood pressure), effects of THC in adults \> 21 years old. The secondary aims of the study are to explore age-related acute effects of THC on electrophysiological indices of information processing (e.g., auditory steady-state respo... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/14/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Age-related Cognitive Decline
Register for Updates
FiberLocker® System Augmentation of Rotator Cuff Repairs
NCT06918041
Recruiting
The purpose of this study is to prospectively evaluate healing, functional clinical outcomes, and safety of arthroscopic rotator cuff repairs augmented with the FiberLocker® System (encompassing the SpeedPatch® PET and the FiberLocker® Instrument SN). The primary outcome measure is healing evaluation based on Magnetic Resonance Imaging (MRI) at a minimum of 6 months post-operatively. The secondary outcome measures are the Sugaya classification, Goutallier Stage and tendon quality based on MRI... Read More
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
08/14/2025
Locations: MedStar Health Research Institute, Columbia, Maryland +1 locations
Conditions: Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder
Register for Updates
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
NCT06974734
Recruiting
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, or pancreatic ductal adenocarcinoma (PDAC); * are able to provide tumor tissue samples; * have measurable disease. All participants will receive while at the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Presbyterian/ St. Lukes Medical Center, Denver, Colorado +8 locations
Conditions: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Register for Updates
Effects of Spirulina Supplementation on Mental Health in Healthy Adults
NCT06936202
Recruiting
Spirulina platensis is a form of cyanobacteria, a blue-green algae, and is a superfood most known for being rich in protein, vitamins and minerals, and healthful phytochemicals. Spirulina supports brain health through neuroprotection offered by its antioxidants, anti-inflammatory properties, and hormone regulation. The aim of this study is to supplement healthy adults from a campus community with 3g of spirulina, daily, for 8 weeks to improve mood and mental acuity in comparison to receiving a... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
08/14/2025
Locations: 850 PBC, Phoenix, Arizona
Conditions: Depression, Mental Acuity
Register for Updates
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272
Recruiting
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as... Read More
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
08/14/2025
Locations: University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017), Iowa City, Iowa +10 locations
Conditions: Malignant Neoplasm
Register for Updates